Part I of this article discussed the potential functional importance of genetic mutations and
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all
available pharmacogenetic data from Medline databases (1970–2003) on the impact that …

Cytochrome P450 CYP2D6 is the most extensively characterized polymorphic drug‐
metabolizing enzyme. A deficiency of the CYP2D6 enzyme is inherited as an autosomal …

The application of pharmacogenetics holds great promise for individualized therapy.
However, it has little clinical reality at present, despite many claims. The main problem is that …

Haloperidol is commonly used in the therapy of patients with acute and chronic
schizophrenia. The enzymes involved in the biotransformation of haloperidol include …

The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine
and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19) …

Objective: This review evaluates the in vitro and in vivo evidence for inhibition of cytochrome
P450 enzymes by the newer antidepressant's and provides clinical recommendations Ior …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and
risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 …